Lymphoma, Large-Cell, Anaplastic - 25 Studies Found
Active, not recruiting |
: Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) :
: 2012-08-02 :
|
Completed |
: Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma :
: 2008-01-21 : Biological: XmAb2513 Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, |
Active, not recruiting |
: Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma :
|
Withdrawn |
: Denileukine Diftitox for Relapsed ALCL : Anaplastic Large-Cell Lymphoma : 2008-12-03 :
|
Recruiting |
: Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL : ALK+ Anaplastic Large Cell Lymphoma : 2015-05-18 :
|
Recruiting |
: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma :
|
Suspended |
: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma :
|
Completed |
: 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma :
|
Recruiting |
: Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + : ALCL : 2016-09-07 : Other: Blood sample |
Completed |
: Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma : Lymphoma : 2011-06-02 :
|